<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712894</url>
  </required_header>
  <id_info>
    <org_study_id>Zhongshan 2006-70</org_study_id>
    <nct_id>NCT00712894</nct_id>
  </id_info>
  <brief_title>Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>EDUCATE-AMI</acronym>
  <official_title>Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of three different vasodilators
      including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during
      direct percutaneous coronary intervention for acute myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No-reflow/slow-flow is a frequent observation during direct PCI for AMI and associated with a
      poor clinical outcome. The present pharmacological management involves the use of different
      vasodilators including nitrates, verapamil, adenosine and nicorandil. But no randomized trial
      has been conducted to assess any of these agents, or to determine the appropriate dosage.
      This prospective randomized study aimed to confirm favorable effects of diltiazem on
      no-reflow/slow-flow during direct PCI for AMI compared with verapamil and nitroglycerin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vessel flow using TIMI flow grade and TIMI frame count</measure>
    <time_frame>post-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiovascular events (MACE)</measure>
    <time_frame>within the first 30 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) through echocardiography</measure>
    <time_frame>at 1 and 30 days post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP levels</measure>
    <time_frame>at 1 and 30 days post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of complete ST-segment resolution</measure>
    <time_frame>3 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak troponin T level</measure>
    <time_frame>24 hours after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>Intracoronary Infusion 400-2000ug</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Intracoronary Infusion 200-1000ug</description>
    <arm_group_label>V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>Intracoronary Infusion 200-1000ug</description>
    <arm_group_label>N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acute myocardial infarction

          -  Vessel TIMI flow &lt; grade Ⅲ post-PCI

        Exclusion Criteria:

          -  Heart failure of New York Heart Association (NYHA) class Ⅲ to class Ⅳ

          -  Sick sinus syndrome

          -  Atrioventricular block (grade Ⅱ and above)

          -  SBP ≤ 90mmHg or cardiogenic shock

          -  Heart Rate ≤60 bpm

          -  Pregnancy

          -  Renal or hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Huang D, Qian J, Ge L, Jin X, Jin H, Ma J, Liu Z, Zhang F, Dong L, Wang X, Yao K, Ge J. REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER). Am Heart J. 2012 Sep;164(3):394-401. doi: 10.1016/j.ahj.2012.06.015.</citation>
    <PMID>22980307</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ge Junbo</investigator_full_name>
    <investigator_title>Director of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>No-reflow phenomenon</keyword>
  <keyword>Vasodilator agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

